Q-omics provides the consensus-scored TUBA3C profile across patient tissues and cancer cell-line models. TUBA3C expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, TUBA3C is differentially expressed in 6, with the highest sampling consensus in KIRC. Additionally, TUBA3C RNA expression shows 5,606 significant pathway-activity associations, with the highest sampling consensus in HNSC. Together, these results highlight KIRP, KIRC, and HNSC as cancer lineages where TUBA3C shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TUBA3C — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TUBA3C survival associations across molecular data types. TUBA3C RNA expression shows survival associations in the most cancer types (19), followed by mutation status (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TUBA3C RNA expression–survival associations across cancer types. High TUBA3C expression shows unfavorable associations in KIRP, KICH, LIHC, KIRC and HNSC, but favorable associations in BRCA. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for TUBA3C RNA expression.
This table summarizes TUBA3C tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 6. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for TUBA3C. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TUBA3C shows lower tumor expression in UCEC and ESCA and higher tumor expression in KIRC, BRCA, LIHC and LUAD. The KIRC box plot shows higher TUBA3C RNA expression in tumor versus normal tissue (log2 FC = +0.200, t-test p = .011).
This table shows molecular features associated with TUBA3C in patient tissues and cancer cell lines. In patient samples, TUBA3C shows the broadest associations at the RNA and protein expression levels, with HNSC recurring as the lineage with the largest associated feature set. In cancer cell lines, TUBA3C RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in CNS and BLOOD_Lymphoma.
